Literature DB >> 28123712

Asymptomatic hyperCKemia during a two-year monitoring period: A case report and literature overview.

Spyridon Klinis1, Athanasios Symeonidis2, Dimitrios Karanasios3, Emmanouil K Symvoulakis4.   

Abstract

High creatine kinase (CK) levels can be associated with many disorders, including neuromuscular, cardiac, metabolic, endocrine and traumatic. Idiopathic hyperCKemia is a diagnostic dilemma for physicians even though its long-term prognosis is usually benign. We report a case of a Caucasian 61-year-old woman who presented as completely asymptomatic to her general practitioner with a serum CK (sCK) level at 6,122 IU/l. A complete diagnostic evaluation, including physical and laboratory examinations, electromyogram and muscle biopsy were negative for any neuromuscular or other disorder. Two years later the patient remains asymptomatic, active and overall healthy but sCK levels remain elevated, ≤6,591 IU/l (>50-fold higher than normal values).

Entities:  

Keywords:  asymptomatic; creatine kinase levels; diagnostic dilemma; monitoring

Year:  2016        PMID: 28123712      PMCID: PMC5244789          DOI: 10.3892/br.2016.822

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  22 in total

1.  Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.

Authors:  M R Weglinski; D J Wedel; A G Engel
Journal:  Anesth Analg       Date:  1997-05       Impact factor: 5.108

2.  Persistent hyperCKemia: fourteen patients studied in retrospect.

Authors:  L M Brewster; M de Visser
Journal:  Acta Neurol Scand       Date:  1988-01       Impact factor: 3.209

3.  EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia.

Authors:  T Kyriakides; C Angelini; J Schaefer; S Sacconi; G Siciliano; J J Vilchez; D Hilton-Jones
Journal:  Eur J Neurol       Date:  2010-04-05       Impact factor: 6.089

4.  Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia.

Authors:  C Fernandez; A Maues de Paula; D Figarella-Branger; M Krahn; R Giorgi; B Chabrol; M-F Monfort; J Pouget; J-F Pellissier
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

5.  Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins.

Authors:  K S Song; P E Scherer; Z Tang; T Okamoto; S Li; M Chafel; C Chu; D S Kohtz; M P Lisanti
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

6.  Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study.

Authors:  J L Joy; S J Oh
Journal:  Muscle Nerve       Date:  1989-03       Impact factor: 3.217

Review 7.  Caveolinopathies: from the biology of caveolin-3 to human diseases.

Authors:  Elisabetta Gazzerro; Federica Sotgia; Claudio Bruno; Michael P Lisanti; Carlo Minetti
Journal:  Eur J Hum Genet       Date:  2009-07-08       Impact factor: 4.246

8.  Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects.

Authors:  Elisabetta D'Adda; Monica Sciacco; Maria Elisa Fruguglietti; Veronica Crugnola; Valeria Lucchini; Filippo Martinelli-Boneschi; Chiara Zecca; Costanza Lamperti; Giacomo Pietro Comi; Nereo Bresolin; Maurizio Moggio; Alessandro Prelle
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

9.  Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene.

Authors:  L Merlini; I Carbone; C Capanni; P Sabatelli; S Tortorelli; F Sotgia; M P Lisanti; C Bruno; C Minetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-07       Impact factor: 10.154

10.  Idiopathic Benign Hyper-CK-Emia.

Authors:  Prashant Kaushik; Anuradha Gonuguntla
Journal:  Int J Biomed Sci       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.